ISSN: 1859 - 2872
Long-term survival prognostic factors of transarterial chemoembolization and stereotactic body radiation therapy for hepatocellular carcinoma
Main Article Content
Keywords
Abstract
Objective: This study was undertaken to investigate the long term prognostic factors of stereotactic body radiation therapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Subject and method: This prospective study was conducted on 42 intermediate-stage HCC patients. The patients received Drug-eluting bead TACE one time subsequent they underwent SBRT. The dose of SBRT was 27.5-48Gy prescribed in 3-5 fractions. Tumor response was evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST). Kaplan-Meier method was used to assess survival. Prognostic factors were analysed by univariate and multivariate analysis. Result: Among 42 patients (male 83.3%), mean age was 60.86 ± 13.25. The 6-, 12-, 24-, and 30-month survival rates were 95.2%, 84.1%, 74.1%, and 68.8%, and mean overall survival (OS) was 27.6 months. Univariate analysis in this study showed that Alpha-fetoprotein level, AFP response and objective response were prognostic factors for OS. Multivariate analysis showed that previous treatment, pretreatment AFP, AFP response, and objective response were prognostic factors for OS. Conclusion: A combination of SBRT and TACE is an effective therapy for intermediate HCC, and OS prognostic factors are pretreatment AFP, AFP response, and objective response.
Article Details
References
2. Nouri YM, Kim JH, Yoon HK et al (2019) Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol 20(1): 34-49.
3. Zhong BY, Wang WS, Zhang S et al (2021) Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists. J Clin Transl Hepatol 9(4): 521-527.
4. Schaub SK, Hartvigson PE, Lock MI et al (2018) Stereotactic body radiation therapy for hepatocellular carcinoma: Current trends and controversies. Technol Cancer Res Treat 17: 1533033818790217.
5. Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68(2): 723-750.
6. Su TS, Lu HZ, Cheng T et al (2016) Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma > 5cm. BMC Cancer 16(1): 834.
7. Jacob R, Turley F, Redden DT et al (2015) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3cm. HPB (Oxford) 17(2): 140-149.
8. Yao E, Chen J, Zhao X et al (2018) Efficacy of Stereotactic Body Radiotherapy for Recurrent or Residual Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. Biomed Res Int 2018: 5481909.
Article Sidebar
